- Report
- March 2019
- 25 Pages
Global
€9660EUR$10,000USD£8,260GBP
- Report
- October 2018
- 293 Pages
Global
From €21251EUR$22,000USD£18,172GBP
- Report
- September 2022
- 120 Pages
Global
From €2415EUR$2,500USD£2,065GBP
- Report
- August 2022
- 111 Pages
Global
From €4347EUR$4,500USD£3,717GBP
- Report
- July 2021
- 116 Pages
Global
From €4299EUR$4,450USD£3,676GBP
- Report
- August 2022
United States
From €1874EUR$1,940USD£1,602GBP
- Report
- August 2022
Global
From €1053EUR$1,090USD£900GBP
- Report
- February 2021
Global
From €2859EUR$2,960USD£2,445GBP
- Drug Pipelines
- February 2023
- 127 Pages
Global
From €10621EUR$10,995USD£9,082GBP
- Report
- February 2023
- 32 Pages
Global
From €3859EUR$3,995USD£3,300GBP
From €6757EUR$6,995USD£5,778GBP
- Clinical Trials
- December 2019
- 193 Pages
Global
From €2415EUR$2,500USD£2,065GBP
- Clinical Trials
- December 2019
- 1881 Pages
Global
From €2415EUR$2,500USD£2,065GBP
- Report
- November 2019
- 186 Pages
Global
From €7723EUR$7,995USD£6,604GBP
- Report
- April 2019
- 75 Pages
Global
From €6757EUR$6,995USD£5,778GBP
- Report
- April 2023
- 240 Pages
Global
From €3477EUR$3,600USD£2,974GBP
- Report
- April 2023
- 82 Pages
North America
From €1449EUR$1,500USD£1,239GBP
- Report
- April 2023
- 94 Pages
Middle East, Africa
From €1449EUR$1,500USD£1,239GBP
- Report
- March 2023
- 203 Pages
Global
From €3477EUR$3,600USD£2,974GBP
- Report
- March 2023
- 74 Pages
North America
From €1449EUR$1,500USD£1,239GBP
Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more